Clinical experiences with venetoclax and other pro-apoptotic agents in lymphoid malignancies: lessons from monotherapy and chemotherapy combination
BH3-mimetics are a novel drug class of small molecule inhibitors of BCL2 family proteins which restore apoptosis in malignant cells. The only currently approved BH3-mimetic, the selective BCL2 inhibitor veneto...
Source: Journal of Hematology and Oncology - Category: Hematology Authors: Thomas E. Lew and John F. Seymour Tags: Review Source Type: research